SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio

January 19, 2024

https://www.prnewswire.com/news-releases/sophia-genetics-enhances-rarecyte-precision-biology-services-portfolio-302038787.html

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel

BOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its  Precision Biology Services portfolio.

Read more at prnewswire.com

Related news for (SOPH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.